---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060244"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:47:25.722919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alector Q3 net loss $44.5M ($0.53/share); cash runway through 2025

## Summary
- Collaboration revenue $9.1M, down from $14.9M YoY; net loss $44.5M vs $46.1M in Q3 2022.
- Cash, equivalents & investments $588.9M; management expects sufficient runway through 2025.
- Completed enrollment in pivotal INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN with 103 symptomatic participants.
- Completed enrollment in INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's; data readout expected Q4 2024.
- Reaffirmed FY 2023 guidance: collaboration revenue $90-100M, R&D $210-220M, G&A $60-65M.

## SEC filing metadata
- accession: 0000950170-23-060244
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/0000950170-23-060244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/alec-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060244
- JSON: https://secwatch.observer/filing/0000950170-23-060244.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060244.txt

## Key facts
- Earnings Releases
  Alector, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/0000950170-23-060244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.